A Community-based Depression Screening Intervention for Middle-aged Suicide

NCT ID: NCT02468466

Last Updated: 2015-06-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

89700 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-01-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to examine the effectiveness of a community-based depression-screening program for suicide prevention among middle-aged adults, the investigators conducted a quasi-experimental intervention study, using a parallel cluster design with communities at municipal level as the unit of allocation and individuals as the unit of analysis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Suicide is a major cause of premature death, particularly among middle-aged adults, in the majority of Western and Asian countries. A strong association of suicide and depression often indicates the necessity of a high-risk approach for suicide prevention. Improvements in identification and treatment can lead to better depression outcomes and suicide prevention. The investigators hypothesize that a 4-year community-based intervention, consisting of universal depression screening and subsequent care support in the target areas and health education programs, would result in reduced suicide rates among the middle-aged adult population in areas with a high suicide rate.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Suicide

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Multi-level suicide prevention programs

The study team, including staff members from the intervention municipalities, provided each municipality with a standardized form of the work plan used in our study. The intervention municipality autonomously conducted the intervention program during the implementation period.

Group Type EXPERIMENTAL

Multi-level suicide prevention programs

Intervention Type BEHAVIORAL

The intervention included both screening and educational components. The screening component invited residents aged 36-64 years to participate in a two-step screening program. In the initial screening, a self-report questionnaire were mailed to all of those residents in the priority districts with a past high suicide rate. The second stage was conducted for the participants who screened positive though a semi-structural interview. Based on the results, participants who were diagnosed with a major depressive episode were provided with a referral to a psychiatry and support for treatment adherence. Written feedback on the screening results was mailed to all respondents. The educational component was implemented through workshops open to the general public (3 times every year) and local public newsletters (twice every year) designed to improve access and adherence to treatment and to reduce stigma associated with suicide and depression.

Community intervention as usual

Suicide prevention program as usual

Group Type ACTIVE_COMPARATOR

Suicide prevention program as usual

Intervention Type BEHAVIORAL

Usual mental health program (not including depression screening among middle-aged)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Multi-level suicide prevention programs

The intervention included both screening and educational components. The screening component invited residents aged 36-64 years to participate in a two-step screening program. In the initial screening, a self-report questionnaire were mailed to all of those residents in the priority districts with a past high suicide rate. The second stage was conducted for the participants who screened positive though a semi-structural interview. Based on the results, participants who were diagnosed with a major depressive episode were provided with a referral to a psychiatry and support for treatment adherence. Written feedback on the screening results was mailed to all respondents. The educational component was implemented through workshops open to the general public (3 times every year) and local public newsletters (twice every year) designed to improve access and adherence to treatment and to reduce stigma associated with suicide and depression.

Intervention Type BEHAVIORAL

Suicide prevention program as usual

Usual mental health program (not including depression screening among middle-aged)

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A municipal area located in the following 4 Aomori Second Medical Zones: Hachinohe, Kamitosan, Aomori, and Tsugaru.
* A municipal area with the higher suicide rate than the prefectural average.
* A municipal area having the sufficient and coverable size to serve the intervention (population 10,000-99,999).

Exclusion Criteria

* A municipal area receiving further intervention including a depression screening for middle-aged adults.
Minimum Eligible Age

36 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aomori University of Health and Welfare

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hirofumi Oyama

Faculty of Health Sciences

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hirofumi Oyama, MD, PhD

Role: STUDY_DIRECTOR

Aomori University of Health and Welfare

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Control group

Fujisaki, Aomori, Japan

Site Status

Intervention group

Gonohe, Aomori, Japan

Site Status

Intervention group

Hashikami, Aomori, Japan

Site Status

Intervention group

Hirakawa, Aomori, Japan

Site Status

Control group

Hiranai, Aomori, Japan

Site Status

Intervention group

Nanaku, Aomori, Japan

Site Status

Intervention group

Oirase, Aomori, Japan

Site Status

Control group

ĹŚwani, Aomori, Japan

Site Status

Control group

Rokunohe, Aomori, Japan

Site Status

Control group

Tohoku, Aomori, Japan

Site Status

Control group

Towada, Aomori, Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

References

Explore related publications, articles, or registry entries linked to this study.

Oyama H, Sakashita T. Effects of universal screening for depression among middle-aged adults in a community with a high suicide rate. J Nerv Ment Dis. 2014 Apr;202(4):280-6. doi: 10.1097/NMD.0000000000000119.

Reference Type BACKGROUND
PMID: 24647214 (View on PubMed)

Oyama H, Sakashita T. Differences in specific depressive symptoms among community-dwelling middle-aged Japanese adults before and after a universal screening intervention. Soc Psychiatry Psychiatr Epidemiol. 2014 Feb;49(2):251-8. doi: 10.1007/s00127-013-0735-6. Epub 2013 Jul 4.

Reference Type BACKGROUND
PMID: 23824236 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KAKENHI #70404829

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.